Edition:
United Kingdom

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
24 Apr 2018
Change (% chg)

$-0.02 (-1.22%)
Prev Close
$1.64
Open
$1.61
Day's High
$1.62
Day's Low
$1.55
Volume
30,366
Avg. Vol
47,084
52-wk High
$6.58
52-wk Low
$0.89

Chart for

About

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189... (more)
No analyst recommendations are available for .

Overall

Beta: 1.58
Market Cap(Mil.): $16.36
Shares Outstanding(Mil.): 12.12
Dividend: --
Yield (%): --

Financials

  CUR.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.24 -- --
ROI: -291.84 14.84 14.38
ROE: -536.03 16.34 16.07

BRIEF-Neuralstem Announces First Surgery Completed In Cervical Cohort Of Phase 1 Clinical Trial In Patients With Chronic Spinal Cord Injury

* NEURALSTEM ANNOUNCES FIRST SURGERY COMPLETED IN CERVICAL COHORT OF PHASE 1 CLINICAL TRIAL IN PATIENTS WITH CHRONIC SPINAL CORD INJURY Source text for Eikon: Further company coverage:

10 Apr 2018

BRIEF-Neuralstem Says At Dec. 31, 2017, Cash And Investments Was $11.7 Mln Compared To $20.2 Mln At Dec. 31, 2016

* NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE

02 Apr 2018

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update

13 Nov 2017

Earnings vs. Estimates